{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-26-000081","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.306448+00:00","generated_at":"2026-05-15T00:40:03.812412+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"confidence":"high","headline":"Cartesian Q1 net loss $39.2M ($1.46/sh) vs $17.7M; cash $120.4M; pipeline advances","bullets":["Net loss widened to $39.2M from $17.7M YoY; higher R&D spend on Phase 3 AURORA trial.","Cash, equivalents & restricted cash $120.4M as of March 31; raised $14.6M via ATM in Q1.","Phase 3 AURORA trial enrollment continues; Phase 2 TRITON in myositis initiated; HELIOS pediatric trial progress.","R&D expenses $19.5M (up 33% YoY) due to AURORA; G&A $7.1M (down 14% YoY).","Cash runway expected into mid-2027, supporting completion of Phase 3 AURORA trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-26-000081","json":"https://secwatch.observer/filing/0001453687-26-000081.json","markdown":"https://secwatch.observer/filing/0001453687-26-000081.md","text":"https://secwatch.observer/filing/0001453687-26-000081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368726000081/0001453687-26-000081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368726000081/rnac-20260430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:40:03.812412+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}